Latest News

Uncategorized

Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice.

Cytoreductive nephrectomy (CN) followed by systemic therapy had been considered the standard of care for metastatic renal cell carcinoma (mRCC) patients since two clinical trials established its role during the cytokines era. With introduction of new and effective drugs, such as vascular endothelial growth factor-targeted therapies, the role of CN started to be challenged. Retrospective […]

Uncategorized

Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma.

Local tumor ablation (LTA) and non-interventional management (NIM) emerged as alternative management options for T1a renal cell carcinoma (RCC). We investigated trends and cancer-specific mortality (CSM) after LTA and NIM, compared to partial nephrectomy (PN). Within the Surveillance, Epidemiology, and End Results database (2004-2015), T1a RCC patients treated with PN, LTA or NIM were identified. […]

Uncategorized

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. We used 1750 MIBC transcriptomic profiles from 16 published datasets […]

Uncategorized

IBCN 2019: Immunological Tumor Microenvironment in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy

Aarhus, Denmark (UroToday.com) Veronika Weyerer from the Institute of Pathology at University Hospital Erlangen presented data investigating the immunological tumor microenvironment in patients with muscle-invasive bladder cancer treated with radical cystectomy, comparing those who had to activate FGFR-3 mutations versus wild-type cases. Analyses were performed comparing tumor mutational burden, neoantigen load, and immune checkpoint gene expression […]

Uncategorized

IBCN 2019: Transcriptomic Data from a Cohort of Neuroendocrine Bladder Cancer Variant Histology Patients

Aarhus, Denmark (UroToday.com) Dr. Woonyoung Choi from Johns Hopkins University in Baltimore, Maryland presented data characterizing transcriptomic data from a cohort of neuroendocrine bladder cancer variant histology patients. 24 neuroendocrine cases and 51 conventional muscle-invasive bladder cancer (MIBC) cases were acquired and RNAseq whole transcriptome analyses were performed on FFPE blocks. Unsupervised hierarchical clustering revealed […]

Uncategorized

IBCN 2019: Twenty-Year Experience of Outcomes from the Swedish National Registry of Urinary Bladder Cancer

Aarhus, Denmark (UroToday.com) Dr. Per-Uno Malmstrom of Uppsala University presented data summarizing a twenty-year experience of outcomes from the Swedish National Registry of Urinary Bladder Cancer. This registry, with participation mandated by local law, was started in 1997 and covers more than 95% of the Swedish patient population. Relative and observed survival from bladder cancer […]

Uncategorized

IBCN 2019: Neoadjuvant Atezolizumab for cT2-4 N0 M0 Muscle-Invasive Bladder Cancer, A Phase II Trial

Aarhus, Denmark (UroToday.com)  Dr. Hyeoung Dong Yuk from Inje University Sanngye Paik Hospital in Seoul, South Korea presented data from a phase II trial investigating the efficacy of neoadjuvant atezolizumab in a patient population (cT2-4N0M0 prior to radical cystectomy (RC) for cystectomy-eligible patients), with endpoints of pathologic responses at the time of radical cystectomy. Patients […]

Uncategorized

IBCN 2019: Non-Cisplatin Based Neoadjuvant Chemotherapy Agents for Cisplatin-Ineligible Patients Prior to Radical Cystectomy

Aarhus, Denmark (UroToday.com) Dr. Vikram Narayan from the University of Texas MD Anderson Cancer Center presented data on behalf of Dr. Justin Matulay and Dr. Neema Navai’s group summarizing a retrospective cohort study investigating the efficacy of non-cisplatin based neoadjuvant chemotherapy agents for cisplatin-ineligible patients prior to radical cystectomy. Over 674 patients were included in […]

Uncategorized

IBCN 2019: The BLASST-1 Phase II Trial, the Efficacy and Safety of Nivolumab with Gemcitabine-Cisplatin – A Neoadjuvant Option for Patients with MIBC

Aarhus, Denmark (UroToday.com) In this oral abstract session, Dr. Shilpa Gupta from the Cleveland Clinic Taussig Cancer Institute presented data on behalf of the Bladder Cancer Signal Seeking Trial (BLASST-1) group. The BLASST-1 trial is a phase II trial investigating the efficacy and safety of nivolumab with gemcitabine-cisplatin (GC) as a neoadjuvant option for patients […]

X